# Corcept Therapeutics Incorporated > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Corcept Therapeutics Incorporated). ## Overview Corcept Therapeutics is a U.S.-based commercial-stage pharmaceutical company focused on medicines that modulate cortisol, with its core marketed product Korlym for patients with hypercortisolism, also known as Cushing’s syndrome. The company also sells an authorized generic version of Korlym in the United States, which broadened its commercial footprint while pressuring average selling prices. Beyond its commercial franchise, Corcept is building a pipeline of selective cortisol modulators for endocrine, oncologic, metabolic and neurologic disorders, including relacorilant, dazucorilant and other proprietary compounds. Its business model combines specialty drug commercialization, physician-focused sales, specialty pharmacy distribution and ongoing clinical development funded largely by product revenue. ## Products & services • Korlym for hypercortisolism (Cushing’s syndrome) • Authorized generic version of Korlym • Selective cortisol modulator pipeline • Clinical development of relacorilant and dazucorilant • Specialty pharmacy and patient support programs - **Commercial products** (100%) — Marketed therapies sold in the U.S. for hypercortisolism, including branded Korlym and its authorized generic. - **Clinical-stage pipeline** (0%) — Selective cortisol modulators in development for endocrine, neurologic, metabolic and oncology indications. - **Patient access services** (0%) — Specialty pharmacy coordination, co-pay support and charitable assistance programs that support access to therapy. - Korlym for treatment of hypercortisolism - Authorized generic version of Korlym - Selective cortisol modulator drug candidates - Relacorilant clinical development programs - Dazucorilant clinical development for ALS - Specialty pharmacy distribution and patient support ## Customers Corcept’s direct customers are physicians treating patients with hypercortisolism, since the company’s sales force calls on endocrinologists and other specialists who diagnose and manage Cushing’s syndrome. The end users are patients with severe cortisol-related disease, but access is mediated through specialty pharmacies, distributors and payer reimbursement systems. A meaningful part of the commercial model depends on commercial insurers, Medicare, Medicaid and other payors that determine coverage, rebates and patient out-of-pocket costs. The company also relies on independent charitable foundations and patient support programs to help financially needy patients obtain therapy. On the development side, its clinical programs serve investigators, trial sites and CROs rather than commercial buyers. - **Physicians treating hypercortisolism** (primary) — Specialists who prescribe Korlym or the generic version based on clinical need and disease severity. - **Patients with Cushing’s syndrome** (primary) — Patients with severe hypercortisolism who use the product and often need access support to afford treatment. - **Specialty pharmacies and distributors** (primary) — Channel partners that dispense, package and deliver the product and manage logistics. - **Commercial and government payors** (primary) — Insurers and public programs that determine reimbursement, rebates and patient affordability. - **Clinical research ecosystem** (secondary) — CROs, investigators and trial sites that support development of relacorilant, dazucorilant and other candidates. - Endocrinologists and other physicians treating hypercortisolism - Patients with Cushing’s syndrome who receive the therapy - Specialty pharmacies and specialty distributors that dispense the product - Commercial insurers, Medicare and Medicaid as reimbursement gatekeepers - Patients needing co-pay and premium assistance through foundations - Clinical trial sites and CROs supporting pipeline development ## Geography Corcept’s commercial revenue is concentrated in the United States, where it markets Korlym and the authorized generic version. The company’s current operating model is therefore highly exposed to U.S. reimbursement policy, specialty pharmacy execution and domestic regulatory scrutiny. Its manufacturing is outsourced to contract manufacturers, including suppliers of the active pharmaceutical ingredient mifepristone and tablet/bottling services, which creates supply-chain dependence rather than owned production capacity. The pipeline has broader geographic intellectual property coverage, but the disclosed commercial business is primarily U.S.-based. As a result, geography matters less as a sales diversification story and more as a concentration risk in one healthcare system. - **United States** (100%) — Commercial products are sold in the U.S.; no non-U.S. revenue disclosed. - Commercial sales are concentrated in the United States - Korlym and the authorized generic are sold in the U.S. only - Manufacturing is outsourced to contract manufacturers - API supply and tablet bottling are dependent on external vendors - Pipeline IP is protected in the U.S. and foreign jurisdictions - U.S. reimbursement and FDA policy are the main geographic exposures ## Strategy Corcept’s strategy is to defend and expand its cortisol-modulation franchise while advancing a broader pipeline of selective cortisol modulators. In the near term, that means maximizing uptake of Korlym and the authorized generic through physician education, specialty pharmacy execution and patient access support. The company is also investing heavily in R&D to move relacorilant, dazucorilant and other compounds through clinical trials, aiming to create follow-on indications beyond hypercortisolism. Because the business is funded by product revenue, maintaining commercial momentum while controlling supply-chain and reimbursement friction is central to sustaining pipeline investment. The company’s strategic position depends on converting its scientific focus on cortisol biology into both durable commercial sales and new label opportunities. - **Defend and expand the commercial hypercortisolism franchise** (short-term) — Current revenue funds the business, so Corcept must preserve prescribing, access and channel execution despite generic competition and pricing pressure. - **Advance the cortisol modulator pipeline** (medium-term) — New indications are needed to diversify the company beyond a single commercial disease area and create longer-term growth. - **Improve patient access and treatment persistence** (short-term) — Specialty drugs depend on reimbursement, affordability and channel reliability, which directly affect realized revenue. - Protect the Korlym franchise in hypercortisolism - Grow volume through the authorized generic while managing pricing pressure - Advance relacorilant and dazucorilant through clinical development - Use physician education to improve diagnosis and treatment of hypercortisolism - Maintain patient access through specialty pharmacy and assistance programs - Reduce supply-chain risk by managing contract manufacturing and inventory ## Risks Corcept is exposed to concentration risk because essentially all commercial revenue comes from one disease area and one U.S. product family, making the business sensitive to prescribing trends, reimbursement and competitive launches. The company specifically cites generic competition for Korlym, public perception and legal restrictions around mifepristone, and changes in drug pricing or coverage policy as threats to sales. Its reliance on contract manufacturers, specialty pharmacies and distributors creates operational risk if any vendor fails to meet demand or transfer services smoothly. More broadly, specialty pharmaceutical companies face regulatory scrutiny, rebate pressure, patient affordability challenges and clinical development risk, especially when the pipeline is still in trial stages. Corcept also faces IT and data-security risk because its operations depend on protected patient, physician and commercial information. - **Generic erosion of Korlym** [high] — A lower-priced generic version can shift volume away from branded product and compress average selling price. - **Mifepristone regulatory and reputational risk** [high] — Public and legislative scrutiny of mifepristone, even outside hypercortisolism use, may limit prescribing or access. - **Reimbursement and pricing pressure** [high] — Government and commercial payors can reduce net realized price through rebates, coverage limits and formulary controls. - **Vendor and supply-chain dependence** [medium] — The company relies on third parties for API, tableting, packaging and specialty pharmacy services. - **Clinical development uncertainty** [medium] — Pipeline candidates may fail in trials or not achieve regulatory approval, limiting future growth options. - Generic competition can reduce Korlym pricing and volume - Mifepristone-related political or legal restrictions may affect demand - Reimbursement changes can limit patient access and net revenue - Dependence on contract manufacturers and specialty pharmacy vendors creates supply risk - Clinical trial failure could delay or eliminate pipeline value - Healthcare policy scrutiny may increase rebates, discounts and compliance burden - IT or data-security failures could disrupt operations and create liability ## Accounting Corcept’s most important accounting judgment is net product revenue, because reported sales are reduced by estimated government rebates, chargebacks, co-pay assistance, distributor discounts and expected returns. Those estimates are updated as new information becomes available, so changes in payer mix, utilization and channel behavior can move revenue and margins even when gross sales are stable. The company also has meaningful quarter-to-quarter variability in revenue and costs because product demand, specialty pharmacy transitions and manufacturing timing can affect shipment patterns and cost of sales. R&D expense is another major judgment area, reflecting clinical trials, personnel, investigational manufacturing and preclinical work, and it can fluctuate as programs move between phases. Investors should also watch inventory and API-related write-offs, since the company has purchased significant quantities of API and outsources manufacturing, which can create obsolescence or supply-chain accounting issues. - **Net product revenue reserves** — Can materially change quarterly revenue and gross margin - **Clinical trial and R&D capitalization policy** — Affects operating loss/profit and comparability across periods - **Inventory and API reserves** — Can affect cost of sales and inventory valuation - **Quarterly channel timing** — Creates seasonality and period-to-period revenue noise - Net product revenue depends on estimates for rebates, chargebacks and returns - Patient co-pay assistance and foundation support reduce recognized revenue - Quarterly revenue can shift with specialty pharmacy and distributor timing - R&D expense varies with clinical trial activity and investigational manufacturing - API inventory and outsourced manufacturing create write-off and reserve risk - Stock repurchases and equity compensation affect equity and cash flow presentation --- *Last updated: 2026-08-11T04:46:26.970236+00:00*